Franklin FTSE South Korea ETF vs Zimmer Biomet Holdings Inc — how do they compare? Franklin FTSE South Korea ETF trades at $58.24 (market cap $1.83B), while Zimmer Biomet Holdings Inc trades at $88.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9.3× Franklin FTSE South Korea ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Franklin FTSE South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FLKR | ZBH | |
|---|---|---|
Market Cap | $1.83B | $16.95B |
Volume | 679,902 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $103.98 |
52-Week Low | $27.09 | $79.58 |
Typical Hold Time | 15 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →